Core Viewpoint - Fulcrum Therapeutics, Inc. is set to present at the 44th Annual J.P. Morgan Healthcare Conference, highlighting its focus on developing small molecules for genetically defined rare diseases [1] Company Overview - Fulcrum Therapeutics is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients with genetically defined rare diseases, particularly in areas with high unmet medical needs [3] - The company's lead clinical program is pociredir, a small molecule aimed at increasing fetal hemoglobin (HbF) expression for treating sickle cell disease (SCD) [3] - Fulcrum employs proprietary technology to identify drug targets that can modulate gene expression, addressing the root causes of gene mis-expression [3] Event Details - The presentation at the J.P. Morgan Healthcare Conference will take place on January 14, 2026, at 10:30 a.m. ET/7:30 a.m. PT [1] - A live webcast of the presentation will be available on Fulcrum Therapeutics' website, with a replay accessible for at least 30 days post-event [2]

Core Insights - Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases [4] - The company will present at the Cantor Fitzgerald 2025 Annual Global Healthcare Conference and the H.C. Wainwright 27th Annual Global Investment Conference [1][2] - Pociredir, Fulcrum's lead clinical program, aims to treat sickle cell disease (SCD) by increasing fetal hemoglobin (HbF) levels [4][5] Company Overview - Fulcrum Therapeutics specializes in small molecules targeting rare diseases with high unmet medical needs [4] - The company utilizes proprietary technology to identify drug targets that modulate gene expression [4] Product Details - Pociredir is an investigational oral small-molecule inhibitor of Embryonic Ectoderm Development (EED) [5] - Initial clinical data showed proof-of-concept with significant increases in HbF levels, indicating potential patient benefits [5] - Pociredir has received FDA Fast Track designation and Orphan Drug Designation for SCD treatment [5] Sickle Cell Disease Context - Sickle cell disease is caused by a mutation in the HBB gene, leading to inefficient oxygen transport and sickle-shaped red blood cells [6] - Patients with SCD face severe clinical consequences, including anemia, pain, and reduced life expectancy [6] Upcoming Events - Fulcrum management will be available for one-on-one meetings during the conferences [3] - Webcast replay links will be available on Fulcrum Therapeutics Investor Relations' Events and Presentations page after the events [3]